Theriva Biologics addresses unusual trading activity on NYSE American Oct 24, 2025 02:32PM
Theriva Biologics raises $4 million through warrant exercise agreement Oct 16, 2025 08:12AM
Theriva Biologics cuts workforce by 32% to focus on cancer drug development Oct 2, 2025 04:04PM
Theriva Biologics (TOVX) Misses Q2 EPS by 193c Aug 11, 2025 10:55AM
Theriva Biologics (TOVX) Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Trial May 27, 2025 08:01AM


May 14, 2025 04:49PM Theriva Biologics (TOVX) Misses Q1 EPS by 155c
May 7, 2025 09:20AM Theriva Biologics (TOVX) Prices 6.82M Share Offering at $1.10/sh
May 7, 2025 07:00AM Theriva Biologics (TOVX) Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01
Mar 31, 2025 08:03AM Theriva Biologics (TOVX) Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE
Dec 5, 2024 08:00AM Theriva Biologics (TOVX) Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01
Nov 12, 2024 04:39PM Theriva Biologics, Inc. (TOVX) Misses Q3 EPS by 652c
Oct 16, 2024 08:02AM Theriva Biologics (TOVX) Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01
Oct 3, 2024 08:01AM Theriva Biologics (TOVX) Announces Positive Outcome of Data and Safety Monitoring Committee Review in Phase 1b/2a Trial of SYN-004
Sep 27, 2024 06:03AM Theriva Biologics (TOVX) Prices 1.43M Share Offering at $1.75/sh
Sep 11, 2024 08:50AM Theriva Biologics (TOVX) Files $200M Mixed Shelf
Sep 10, 2024 05:07PM Theriva Biologics (TOVX) Files for 2.17M Share and Warrant Offering
Aug 16, 2024 04:05PM Theriva Biologics (TOVX) Announces Reverse Stock Split
Aug 13, 2024 10:33AM Theriva Biologics, Inc. (TOVX) Misses Q2 EPS by 24c
Jul 31, 2024 08:16AM Theriva Biologics (TOVX) Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma